Alirocumab may reduce stroke risk without increasing odds of hemorrhage

New data from the ODYSSEY Outcomes trial show that alirocumab is effective at reducing risk for any stroke without increasing risk for hemorrhagic stroke.In a cohort of 18,924 patients with recent ACS and elevated LDL despite intensive statin therapy, alirocumab (Praluent, Sanofi/Regeneron) was effective in reducing the risk for any stroke (HR = 0.72; 95% CI, 0.57-0.91) and ischemic stroke (HR =

Read the full article here

Related Articles